Returns On Capital At OrbusNeich Medical Group Holdings (HKG:6929) Have Stalled
Returns On Capital At OrbusNeich Medical Group Holdings (HKG:6929) Have Stalled
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expanding base of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. However, after briefly looking over the numbers, we don't think OrbusNeich Medical Group Holdings (HKG:6929) has the makings of a multi-bagger going forward, but let's have a look at why that may be.
寻找具有大幅增长潜力的企业并不容易,但如果我们看几个关键的财务指标,这是可能的。首先,我们希望看到经过验证的 返回 关于正在增加的资本使用率(ROCE),其次是扩大 基础 所用资本的比例。基本上,这意味着公司拥有可以继续进行再投资的盈利计划,这是复合机器的特征。但是,在简短地研究了这些数字之后,我们认为OrbusNeich Medical Group Holdings(HKG: 6929)在未来不具备多袋公司的实力,但让我们来看看为什么会这样。
Return On Capital Employed (ROCE): What Is It?
资本使用回报率(ROCE):这是什么?
Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. Analysts use this formula to calculate it for OrbusNeich Medical Group Holdings:
为了澄清一下你是否不确定,ROCE是评估公司从投资于其业务的资本中获得多少税前收入(按百分比计算)的指标。分析师使用这个公式来计算奥布斯内希医疗集团控股的金额:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
已动用资本回报率 = 息税前收益 (EBIT) ¥(总资产-流动负债)
0.097 = US$34m ÷ (US$373m - US$22m) (Based on the trailing twelve months to June 2023).
0.097 = 3,400万美元 ÷(3.73亿美元至2200万美元) (基于截至 2023 年 6 月的过去十二个月)。
So, OrbusNeich Medical Group Holdings has an ROCE of 9.7%. On its own that's a low return on capital but it's in line with the industry's average returns of 10.0%.
因此,OrbusNeich Medical Group Holdings的投资回报率为9.7%。这本身就是很低的资本回报率,但与该行业10.0%的平均回报率一致。
![roce](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240302/0-7ad6fe13f3bf9d07fb1c966d55f99d72-0-503ba5a3b5687cd659b34592ce4c77c3.png/big)
Above you can see how the current ROCE for OrbusNeich Medical Group Holdings compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering OrbusNeich Medical Group Holdings for free.
上面你可以看到OrbusNeich Medical Group Holdings当前的投资回报率与其先前的资本回报率相比如何,但从过去可以看出来的只有那么多。如果你愿意,你可以免费查看报道OrbusNeich Medical Group Holdings的分析师的预测。
What The Trend Of ROCE Can Tell Us
ROCE 的趋势能告诉我们什么
The returns on capital haven't changed much for OrbusNeich Medical Group Holdings in recent years. Over the past two years, ROCE has remained relatively flat at around 9.7% and the business has deployed 135% more capital into its operations. This poor ROCE doesn't inspire confidence right now, and with the increase in capital employed, it's evident that the business isn't deploying the funds into high return investments.
近年来,OrbusNeich Medical Group Holdings的资本回报率没有太大变化。在过去的两年中,投资回报率一直相对持平,约为9.7%,该业务在运营中投入的资金增加了135%。这种糟糕的投资回报率目前并不能激发信心,随着所用资本的增加,很明显,该企业没有将资金部署到高回报的投资中。
On a side note, OrbusNeich Medical Group Holdings has done well to reduce current liabilities to 6.0% of total assets over the last two years. This can eliminate some of the risks inherent in the operations because the business has less outstanding obligations to their suppliers and or short-term creditors than they did previously.
顺便说一句,在过去两年中,OrbusNeich医疗集团控股公司在将流动负债减少至总资产的6.0%方面做得很好。这可以消除运营中固有的某些风险,因为企业对供应商和/或短期债权人的未清债务比以前少。
In Conclusion...
总之...
In conclusion, OrbusNeich Medical Group Holdings has been investing more capital into the business, but returns on that capital haven't increased. And investors appear hesitant that the trends will pick up because the stock has fallen 61% in the last year. All in all, the inherent trends aren't typical of multi-baggers, so if that's what you're after, we think you might have more luck elsewhere.
总之,OrbusNeich Medical Group Holdings一直在向该业务投入更多资金,但该资本的回报率并未增加。投资者似乎对趋势能否回升犹豫不决,因为该股去年下跌了61%。总而言之,多装袋机的固有趋势并不常见,因此,如果您想要这样做,我们认为您在其他地方可能会有更多的运气。
While OrbusNeich Medical Group Holdings doesn't shine too bright in this respect, it's still worth seeing if the company is trading at attractive prices. You can find that out with our FREE intrinsic value estimation for 6929 on our platform.
尽管OrbusNeich Medical Group Holdings在这方面的表现并不太明显,但该公司的交易价格是否具有吸引力,仍然值得一看。您可以在我们的平台上通过我们对6929的免费内在价值估算中找到答案。
If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.
如果你想寻找收益丰厚的稳健公司,可以免费查看这份资产负债表良好且股本回报率可观的公司名单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。